Metabolic manipulation in chronic heart failure: Study protocol for a randomised controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Beadle, Roger M ^a,c   Williams, Lynne K ^b   Abozguia, Khaild ^c   Patel, Kiran ^c   Leon, Francisco L ^c   Yousef, Zaheer ^d   Wagenmakers, Anton ^c   Frenneaux, Michael P ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; PERHEXILINE MALEATE; PLACEBO; TRIMETAZIDINE; CARDIOVASCULAR AGENT; PERHEXILINE;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG MONITORING; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; METABOLIC MANIPULATION; METABOLIC REGULATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY QUOTIENT; TREATMENT DURATION; UNIVERSITY HOSPITAL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONVALESCENCE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; ENERGY METABOLISM; HEART FAILURE; HEART MUSCLE; HEART STROKE VOLUME; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLACEBO EFFECT; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ADENOSINE TRIPHOSPHATE; CARDIOMYOPATHY, DILATED; CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; DRUG MONITORING; ECHOCARDIOGRAPHY, DOPPLER; ENERGY METABOLISM; GREAT BRITAIN; HEART CATHETERIZATION; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MYOCARDIUM; PERHEXILINE; PHOSPHOCREATINE; PLACEBO EFFECT; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RESEARCH DESIGN; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 79957925338     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-140     Document Type: Article

References (22)

1. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'Malignant' Than Cancer? Five-Year Survival Following a First Admission for Heart Failure. Eur J Heart Fail 2001, 3(3):315-22. 10.1016/S1388-9842(00)00141-0, 11378002.
2. Brown AM, Cleland JG. Influence of Concomitant Disease on Patterns of Hospitalization in Patients With Heart Failure Discharged From Scottish Hospitals in 1995. Eur Heart J 1998, 19(7):1063-9. 10.1053/euhj.1997.0859, 9717042.
3. Khand A, Gemmel I, Clark AL, Cleland JG. Is the Prognosis of Heart Failure Improving?. J Am Coll Cardiol 2000, 36(7):2284-6. 10.1016/S0735-1097(00)00995-5, 11127474.
4. Bottomley PA, Wu KC, Gerstenblith G, Schulman SP, Steinberg A, Weiss RG. Reduced Myocardial Creatine Kinase Flux in Human Myocardial Infarction: an in Vivo Phosphorus Magnetic Resonance Spectroscopy Study. Circulation 2009, 119(14):1918-24. 10.1161/CIRCULATIONAHA.108.823187, 2743337, 19332463.
5. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, Mader H, Kromer EP, Riegger GA, Lackner K. 31P Magnetic Resonance Spectroscopy in Dilated Cardiomyopathy and Coronary Artery Disease. Altered Cardiac High-Energy Phosphate Metabolism in Heart Failure. Circulation 1992, 86(6):1810-8.
6. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiol Rev 2005, 85(3):1093-129. 10.1152/physrev.00006.2004, 15987803.
7. Bouche P, Bousser MG, Peytour MA, Cathala HP. Perhexiline Maleate and Peripheral Neuropathy 1. Neurology 1979, 29(5):739-43.
8. Roberts RK, Cohn D, Petroff V, Seneviratne B. Liver Disease Induced by Perhexiline Maleate 2. Med J Aust 1981, 2(10):553-4.
9. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly RA, Hartley LH, Smith TW, Antman EM. Efficacy and Safety of Perhexiline Maleate in Refractory Angina. A Double-Blind Placebo-Controlled Clinical Trial of a Novel Antianginal Agent 1. Circulation 1990, 81(4):1260-70. 10.1161/01.CIR.81.4.1260, 2180591.
10. Fragasso G, Perseghin G, De CF, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del MA, Margonato A. Effects of Metabolic Modulation by Trimetazidine on Left Ventricular Function and Phosphocreatine/Adenosine Triphosphate Ratio in Patients With Heart Failure. Eur Heart J 2006, 27(8):942-8.
11. Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy. Circulation 2010, 122(16):1562-9. 10.1161/CIRCULATIONAHA.109.934059, 20921440.
12. Vanhamme L, Sundin T, Hecke PV, Huffel SV. MR Spectroscopy Quantitation: a Review of Time-Domain Methods. NMR Biomed 2001, 14(4):233-46. 10.1002/nbm.695, 11410941.
13. Conway MA, Bottomley PA, Ouwerkerk R, Radda GK, Rajagopalan B. Mitral Regurgitation: Impaired Systolic Function, Eccentric Hypertrophy, and Increased Severity Are Linked to Lower Phosphocreatine/ATP Ratios in Humans. Circulation 1998, 97(17):1716-23.
14. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2(5):358-67.
15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for Chamber Quantification: a Report From the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction With the European Association of Echocardiography, a Branch of the European Society of Cardiology 1. J Am Soc Echocardiogr 2005, 18(12):1440-63. 10.1016/j.echo.2005.10.005, 16376782.
16. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. J Am Soc Echocardiogr 2009, 22(2):107-33. 10.1016/j.echo.2008.11.023, 19187853.
17. Alam M, Wardell J, Andersson E, Samad BA, Nordlander R. Characteristics of Mitral and Tricuspid Annular Velocities Determined by Pulsed Wave Doppler Tissue Imaging in Healthy Subjects. J Am Soc Echocardiogr 1999, 12(8):618-28. 10.1053/je.1999.v12.a99246, 10441217.
18. Fick A. Uber Die Messung Den Blutquantums in Der Herzventrikeln. Sitzungb Phys Med Gez Wurzberg 1870, 16.
19. Gibbs CL. Cardiac Energetics. Physiol Rev 1978, 58(1):174-254.
20. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortality in Patients With Dilated Cardiomyopathy. Circulation 1997, 96(7):2190-6.
21. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic Modulation With Perhexiline in Chronic Heart Failure: a Randomized, Controlled Trial of Short-Term Use of a Novel Treatment. Circulation 2005, 112(21):3280-8. 10.1161/CIRCULATIONAHA.105.551457, 16301359.
22. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a Meta-Analysis of Randomised Controlled Trials in Heart Failure. Heart 2011, 97(4):278-86. 10.1136/hrt.2010.208751, 21134903.